MCM
ZYNE

Moore Capital Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Moore Capital Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-35,000
Closed -$704K – 251
2017
Q1 		$704K Buy
+35,000
New +$696K 0.02% 173

Other funds holding ZYNE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FTIOP
Fiduciary Trust International of Pennsylvania Radnor, Pennsylvania $2.14B AUM 3.72% 1-Year Est. Return

Moore Capital Management's ZYNE Position: Q2 2017 in Review

Moore Capital Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2017, closing a stake of 35,000 shares — an estimated $704K sold.

Moore Capital Management first reported a position in ZYNE in Q1 2017 and held it in 1 quarter. The position peaked at $704K in Q1 2017. 66 funds tracked by Wall St. Rank hold ZYNE as of Q2 2017.

  • Moore Capital Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2017 after selling out during the quarter.
  • Moore Capital Management sold 35,000 Zynerba Pharmaceuticals, Inc shares in Q2 2017, an estimated $704K.
  • Moore Capital Management first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2017 and held it in 1 quarter.
  • Moore Capital Management's Zynerba Pharmaceuticals, Inc position peaked at $704K in Q1 2017.
  • 66 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2017.

Based on Moore Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.